Clinical Trial Update: A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma [Phase 2]

View source ↗

Summary

A Phase 2 multi-dose study of a self-administered intranasal treatment (AD17002) for eosinophilic asthma is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Asthma

Drugs mentioned

• AD17002

Snippet

Sponsor: Advagene Biopharma Co. Ltd. | Conditions: Eosinophilic Asthma | Phase 2 | Status: NOT_YET_RECRUITING